Drug intelligence / Profile preview

BBV152C

Development stage: Unknown
Lead developer: Bharat Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BBV152C is a component of BBV152 (Covaxin), a whole virion inactivated SARS-CoV-2 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). It is formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) as an adjuvant. The vaccine is manufactured using a vero cell platform (CCL-81) and has shown efficacy against symptomatic and asymptomatic COVID-19, including protection against the Delta variant.

Brand names: Covaxin
Other names: Whole-Virion Inactivated SARS-CoV-2 Vaccine

Targets

SARS-CoV-2

Beyond the preview

Go deeper on BBV152C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBV152C.

Explore the full profile